Abstract
Background. A 62-year-old postmenopausal woman with a family history of breast cancer, mild gastroesophageal reflux disease, iron-deficient anemia and declining BMD was seen in a specialist center for the evaluation and management of osteoporosis.
Investigations. Analysis of tissue transglutaminase IgA, endoscopic biopsy, serial BMD scans, FRAX® calculation of osteoporotic fracture risk, Gail model calculation of breast cancer risk, assessment of blood vitamin D concentration and secondary evaluation for osteoporosis.
Diagnosis. Osteoporosis, persistent after 12 years of hormone replacement therapy, and celiac disease.
Management. The patient was initially treated for bone loss with postmenopausal hormone replacement therapy. DXA analyses showed a continued decline in BMD despite adequate replacement of calcium and vitamin D levels and withdrawal of gluten from the patient's diet. An oral bisphosphonate was recommended with plans to reassess BMD after 1 year.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cauley, J. A. et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290, 1729–1738 (2003).
Watts, N. B., Lewiecki, E. M., Miller, P. D. & Baim, S. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J. Clin. Densitom. 11, 473–477 (2008).
World Health Organization Collaborating Centre for Metabolic Bone Diseases WHO Fracture Risk Assessment Tool [online] (2009).
National Osteoporosis Foundation [online] (2009).
Gail, M. H. et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst. 81, 1879–1886 (1989).
Rostom, A. et al. The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology 128 (Suppl. 1) S38–S46 (2005).
Rostom, A., Murray, J. A. & Kagnoff, M. F. American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 131, 1981–2002 (2006).
AGA Institute. AGA Institute medical position statement on the diagnosis and management of celiac disease. Gastroenterology 131, 1977–1980 (2006).
US Department of Health and Human Services. National Institutes of Health Consensus Development Conference Statement [online], (2004).
Niewinski, M. M. Advances in celiac disease and gluten-free diet. J. Am. Diet Assoc. 108, 661–672 (2008).
Pietzak, M. M. Follow-up of patients with celiac disease: achieving compliance with treatment. Gastroenterology 128 (Suppl. 1), S135–S141 (2005).
Chapuy, M. C. et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int. 7, 439–443 (1997).
Olmos, M. et al. Systematic review and meta-analysis of observational studies on the prevalence of fractures in coeliac disease. Dig. Liver Dis. 40, 46–53 (2008).
Legroux-Gérot, I. et al. Screening for celiac disease in patients with osteoporosis. Joint Bone Spine 76, 162–165 (2009).
Kavuncu, V., Dundar, U., Ciftci, I. H., Evcik, D. & Yigit, I. Is there any requirement for celiac disease screening routinely in postmenopausal women with osteoporosis? Rheumatol. Int. 29, 841–845 (2009).
Yu, E. W. et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif. Tissue Int. 83, 251–259 (2008).
Roux, C. et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif. Tissue Int. 84, 13–19 (2009).
Mautalen, C. et al. Effect of treatment on bone mass, mineral metabolism, and body composition in untreated celiac disease patients. Am. J. Gastroenterol. 92, 313–318 (1997).
National Institute of Diabetes and Digestive and Kidney Diseases National Digestive Diseases Information Clearinghouse [online], (2009).
Stenson, W. F., Newberry, R., Lorenz, R., Baldus, C. & Civitelli, R. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch. Intern. Med. 165, 393–399 (2005).
Acknowledgements
Written consent for publication was obtained from the patient. Charles P. Vega, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the MedscapeCME-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J. V. Pinkerton declares associations with the following companies: Amgen (consultant), Boehringer Ingelheim (consultant), Eli Lilly (consultant), NovoNordisk (consultant), Pfizer (grant/research support), Wyeth (consultant, grant/research support). The other authors, the Journal Editor V. Heath and the CME questions author C. P. Vega declare no competing interests.
Rights and permissions
About this article
Cite this article
Pinkerton, J., Dalkin, A., Crowe, S. et al. Treatment of postmenopausal osteoporosis in a patient with celiac disease. Nat Rev Endocrinol 6, 167–171 (2010). https://doi.org/10.1038/nrendo.2009.272
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.272